Breathing Should Be Easy

We're developing a novel inhaled therapy to treat respiratory disease

1 in 10 people have asthma costing $90 billion annually in the US

33 million worldwide suffer from inadequately controlled asthma^1,2

COPD recognized by WHO as third leading cause of death worldwide

Non-CF Bronchiectasis (NCFB) is an orphan disease with high unmet need and few treatment options

Idiopathic Pulmonary Fibrosis (IPF) is an orphan disease with median survival of only 3 – 5 years

In asthma and COPD, smooth muscle tightening, excess mucus production, inflammation and infections all contribute to airway narrowing

In bronchiectasis persistent infections, inflammation, mucus hypersecretion, and airway enlargement leads to cough and poor lung function

In IPF, inflammatory processes lead to mucus, fibrosis, and thickening of small airways resulting in trouble breathing

Healthy airways are unobstructed to support easy breathing

1 in 10 people have asthma costing $90 billion annually in the US

33 million worldwide suffer from inadequately controlled asthma^1,2

COPD recognized by WHO as third leading cause of death worldwide

Non-CF Bronchiectasis (NCFB) is an orphan disease with high unmet need and few treatment options

Idiopathic Pulmonary Fibrosis (IPF) is an orphan disease with median survival of only 3 – 5 years

In asthma and COPD, smooth muscle tightening, excess mucus production, inflammation and infections all contribute to airway narrowing

In bronchiectasis persistent infections, inflammation, mucus hypersecretion, and airway enlargement leads to cough and poor lung function

In IPF, inflammatory processes lead to mucus, fibrosis, and thickening of small airways resulting in trouble breathing

Healthy airways are unobstructed to support easy breathing

How We are Simplifying Respiratory Health

By focusing on the ROOT CAUSES OF DISEASE - knowing how to SHUT IT DOWN - and empowering patients to TAKE CONTROL